Viking Therapeutics (VKTX) Common Equity (2014 - 2026)

Viking Therapeutics has disclosed Common Equity across 13 years of filings, most recently posting $501.9 million for Q1 2026.

• Common Equity for Q1 2026 came in at $501.9 million, down 40.74% year-over-year; the trailing twelve-month figure through Mar 2026 was $501.9 million (down 40.74% YoY), and the FY2025 annual result was $639.1 million, down 27.4% from the prior year.
• Common Equity came in at $501.9 million for Q1 2026 at Viking Therapeutics, down from $639.1 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $933.9 million in Q1 2024 to a low of $134.1 million in Q1 2023.
• The 5-year median for Common Equity is $501.9 million (2026), against an average of $530.8 million.
• Across the five-year window, Common Equity surged 596.6% in 2024 and slumped 40.74% in 2026, its largest moves.
• Viking Therapeutics' Common Equity stood at $145.3 million in 2022, then surged by 139.76% to $348.4 million in 2023, then surged by 152.65% to $880.3 million in 2024, then decreased by 27.4% to $639.1 million in 2025, then declined by 21.46% to $501.9 million in 2026.
• The last three Common Equity figures came in at $501.9 million (Q1 2026), $639.1 million (Q4 2025), and $713.0 million (Q3 2025), per Business Quant data.